Blockbuster drugs in tumor chemotherapy, simultaneous filing in China and Europe
Albumin-bound paclitaxel(Apexelsin) takes the advantage of nanotechnology to combine the drug substance
with human albumin to generate nanoparticles with improved solubility, featured by "Three Highs
and One Low", i.e. high dose, high distribution in tumor tissue, high efficacy, and low toxicity.
Albumin-bound paclitaxel is recommended by the NCCN and CSCO guidelines for the treatment of
breast cancer. It is the only product in China that is applied simultaneously in China, the United
States, and the European Union and the NDA in China and European Union has been accepted for
review.
Indications
Metastatic breast cancer after failure of combination chemotherapy or breast cancer
within 6 months after adjuvant chemotherapy.
Recommended reading
Unlocking the Power of Albumin-Bound Paclitaxel: Quality, Affordability, and Innovation
Exploring the Power of Albumin-Bound Paclitaxel: A Breakthrough in Cancer Treatment
Reviews
There are no reviews yet.